It blocks the phosphorylation of FAK Tyr397 and inhibits FAK overexpression in a dose-dependent manner, resulting in antitumor effects in rhabdomyosarcoma (RMS) [41], epithelial ovarian cancer (EOC) [42, 43] and PDAC [29]. The gene discussed is PTK2; the disease is ovarian carcinoma.